论文部分内容阅读
目的:研究复合前列腺特异性抗原、总前列腺特异性抗原及其比值在鉴别前列腺癌和良性前列腺增生中的应用价值。方法:采用化学发光法检测30例前列腺癌患者、40例良性前列腺增生患者和30例对照组患者复合前列腺特异性抗原、总前列腺特异性抗原,计算并比较其比值。结果:前列腺癌患者的复合前列腺特异性抗原、总前列腺特异性抗原均高于对照组和良性前列腺增生患者,差异均具有统计学意义(P<0.05);其比值前列腺癌患者高于良性前列腺增生患者,差异有统计学意义(P<0.05);其相关性和共线性均不如前列腺癌组病例。结论:前列腺癌患者总前列腺特异性抗原的升高以复合前列腺特异性抗原升高为主,测定复合前列腺特异性抗原更有意义,结合其比值进行综合分析可以有效区分良性前列腺增生和前列腺癌。
Objective: To study the value of compound prostate-specific antigen, total prostate-specific antigen and its ratio in the differential diagnosis of prostate cancer and benign prostatic hyperplasia. Methods: Chemiluminescence was used to detect prostate specific antigen and total prostate specific antigen in 30 patients with prostate cancer, 40 patients with benign prostatic hyperplasia and 30 patients with control group. The ratios of these patients were calculated and compared. Results: Prostate-specific prostate cancer antigen and total prostate specific antigen were significantly higher in patients with prostate cancer than those in control group and benign prostatic hyperplasia patients (P <0.05). The proportion of prostate cancer patients was higher than that of benign prostatic hyperplasia Patients, the difference was statistically significant (P <0.05); its correlation and collinearity are not as good as the case of prostate cancer patients. CONCLUSIONS: Prostate cancer patients with elevated total prostate-specific antigen to prostate specific antigen-specific prostate composite antigen specific determination of composite prostate more meaningful, combined with the ratio of a comprehensive analysis can effectively distinguish between benign prostatic hyperplasia and prostate cancer.